SCYNERGIA
A Phase 2 Trial - Combination Therapy of Ibrexafungerp (SCY-078) with Voriconazole in Patients with Invasive Pulmonary Aspergillosis
Learn more hereOngoing Clinical Trials
FURI
Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp (SCY-078) in Patients with Refractory or Intolerant Fungal Diseases
Learn more here
CARES
Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp (SCY-078) in Patients with Candidiasis Caused by Candida Auris
Learn more here
CANDLE
Ibrexafungerp for Recurrent Vulvovaginal Candidiasis (RVVC)
SCY-0789-304 is a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC). Enrollment is complete.
ClinicalTrials.gov Identifier: NCT04029116
Learn more hereInterested In Our Clinical Trials?
If you have any questions, please contact us at ClinicalTrials@SCYNEXIS.com.